Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients.
暂无分享,去创建一个
David A. Williams | J. Manis | S. Nikiforow | L. Biasco | W. London | A. Biffi | M. Heeney | H. Daley | M. Asmal | M. Armant | H. Trébéden‐Nègre | Erica B Esrick | F. J. Pierciey | C. Baricordi
[1] M. Sadelain,et al. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results , 2018, Haematologica.
[2] J. Tisdale,et al. Hematopoietic stem cell mobilization with plerixafor in sickle cell disease , 2018, Haematologica.
[3] Weiliang Shi,et al. Single-Agent Plerixafor Mobilization to Collect Autologous Stem Cells for Use in Gene Therapy for Severe Sickle Cell Disease , 2018 .
[4] S. Orkin,et al. Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies , 2018, British journal of haematology.
[5] A. Miccio,et al. Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion , 2018, Haematologica.
[6] G. Stamatoyannopoulos,et al. Poor stem cell harvest may not always be related to poor mobilization: lessons gained from a mobilization study in patients with β‐thalassemia major , 2017, Transfusion.
[7] G. Veres,et al. Gene Therapy in a Patient with Sickle Cell Disease: Brief Report , 2017, The New England journal of medicine.
[8] N. Geller,et al. Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial , 2016, Haematologica.
[9] J. Tisdale,et al. Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease , 2016 .
[10] S. Orkin,et al. Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. , 2016, Blood.
[11] R. Mcpherson,et al. Harvesting autologous stem cells from a patient with red blood cell abnormalities of β‐thalassemia intermedia , 2014, Transfusion.
[12] J. Dipersio,et al. Advances in stem cell mobilization. , 2014, Blood reviews.
[13] G. Stamatoyannopoulos,et al. Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major. , 2013, Human gene therapy.
[14] Tso-fu Wang,et al. Poor harvest of peripheral blood stem cell in donors with microcytic red blood cells , 2013, Transfusion.
[15] J. Dipersio,et al. Advances in stem cell mobilization. , 2012, Blood reviews.
[16] P. Hari,et al. Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[17] M. Cottler-Fox,et al. Validation of a formula for predicting daily CD34(+) cell collection by leukapheresis. , 2012, Cytotherapy.
[18] Elisa Laurenti,et al. Hematopoiesis: a human perspective. , 2012, Cell stem cell.
[19] G. Stamatoyannopoulos,et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[20] A. Nademanee,et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Nademanee,et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. , 2009, Blood.
[22] J. Tisdale,et al. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? , 2009, Cytotherapy.
[23] R. Vij,et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. , 2008, Blood.
[24] S. Heimfeld,et al. Collection of blood stem cells from patients with sickle cell anemia. , 2005, Blood cells, molecules & diseases.
[25] J. Dipersio,et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. , 2005, Blood.
[26] B. Wood,et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. , 2003, Blood.
[27] J. Prchal,et al. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. , 2001, Blood.
[28] J. Laver,et al. Granulocytosis causing sickle-cell crisis , 1998, The Lancet.